RESUMO
Background: Immunotherapy is the first-line treatment in patients with advanced microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) colorectal cancer (CRC). Although immune checkpoint inhibitors (ICIs) for locally advanced rectal cancer (LARC) are not yet a standard, the results are very encouraging and raise the question of whether patients with clinical complete response (cCR) could receive nonoperative management (NOM). However, different patterns of response have challenged management strategies. Case Description: A 34-year-old woman diagnosed with dMMR LARC started treatment with capecitabine 2,000 mg/m2 on day 1 to 14 and oxaliplatin 130 mg/m2 on day 1 and every 21 days. Magnetic resonance imaging (MRI), performed three cycles later, showed local progression of the primary rectal lesion, which at that time had new peritoneal reflex involvement. A new hepatic lesion in segment V was observed. Due to disease progression, she was administered pembrolizumab 200 mg every 21 days. After three cycles, a discordant radiological response was observed on a new MRI scan that showed a complete response of the liver lesion and magnetic resonance tumor regression grade (mrTRG) 1 in the rectum. However, new involvement of the mesentery and enlargement of the regional lymph nodes (LNs) were also evident. A new colonoscopic biopsy was performed, showing no cancerous cells. She underwent surgery on the rectum and liver lesion. Pathology showed a complete response of the rectal wall and liver lesion, but 1 of 22 LNs was positive for adenocarcinoma (ypT0 N1 M0). The patient continued on pembrolizumab, and 14 months after surgery, she had not relapsed. Conclusions: Neoadjuvant immunotherapy for rectal cancer requires new recommendations for the assessment of clinical response. Pseudoprogression should be ruled out as an atypical response before deciding on surgical treatment. We propose an algorithm to address pseudoprogression in this setting.
RESUMO
El desarrollo de biomateriales bioactivos como andamios para la osteointegración o regeneración de tejidos ha dado grandes pasos, el presente trabajo, muestra los procesos de síntesis de biomateriales como la hidroxiapatita, biomateriales del sistema SiO2-CaO-P2O5-Al2O3 y biovidrios del sistema SiO2.Li2O, se ha logrado caracterizar los biomateriales obtenidos, con resultados similares a los de otros investigadores por técnicas con la Difracción de Rayos X y la Microscopía Electrónica de Barrido, se ha evaluado su comportamientoen pruebas de biocompatibilidad y bioactividad en soluciones de Plasma Rico en Factores de Crecimiento y Fluido corporal simulado, seguidamente y con el fin de evaluar la incorporación de sustancias antibacteriales se ha dopado uno de ellos con plata, logrando determinar que el material tiene esta capacidad, estos resultados son los primeros pasos para encarar posteriores trabajos en el campo de la Ingeniería Tisular en Bolivia, y de esta forma encarar procesos de ostointegración y regeneración de tejidos en general.
The development of bioactive biomaterials as scaffolds for osseointegration or tissue regeneration has taken great steps, the present work shows the synthesis processes of biomaterials such as hydroxyapatite, biomaterials of the SiO2-CaO-P2O5-Al2O3 system and bio-libraries of the SiO2 system. Li2O, it has been possible to characterize the biomaterials obtained, with results similar to those of other researchers by techniques with X-ray Diffraction and Scanning Electron Microscopy, their behavior in biocompatibility and bioactivity tests in Plasma Rico solutions has been evaluated in Growth factors and simulated body fluid, then and in order to evaluate the incorporation of antibacterial substances, one of them has been doped with silver, managing to determine that the material has this capacity, these results are the first steps to face further work in the field of Tissue Engineering in Bolivia, and thus face Osteintegration processes and tissue regeneration in general.